Programmed Cell Death in Cancer Progression and Therapy

Volume 615 of the series Advances in Experimental Medicine and Biology pp 127-158

Trail Receptors: Targets for Cancer Therapy

  • Robin C. HumphreysAffiliated withDevelopment Sciences and Research, Human Genome SciencesOncology Research Department, Human Genome Sciences
  • , Wendy HalpernAffiliated withHuman Genome Sciences, Pathology, Pharmacokinetics and Toxicology

* Final gross prices may vary according to local VAT.

Get Access

A human tumor cell's ability to avoid the normal regulatory mechanisms of cell growth, division, and death are the hallmarks of transformation and cancer. Numerous novel therapeutic agents currently in preclinical or clinical evaluation aim to revive the normal regulation or evade these regulatory defects and induce growth arrest and cell death. One of the cell death pathways that has garnered significant interest, as a potential target for therapeutic intervention, is the programmed cell death pathway regulated by the tumor necrosis factor-related apoptosis-inducing ligand receptors (TRAIL-RS). Receptor agonist molecules including forms of the native ligand and monoclonal antibodies are being developed and tested as therapeutics in the treatment of human cancer.


apoptosis monoclonal antibody agonist TRAIL TRAIL receptor